Delivery Order SPE2DR25D9131-SPE2DR26FCPH4
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,481.25 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/ml on January 9, 2026, with completion targeted for January 12, 2026. This firm fixed-price delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, that specializes in...
- The Defense Logistics Agency issued a delivery order valued at $14,962.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA PEN 30 MG/ML. This firm fixed-price delivery order, awarded on January 5, 2026, with an ultimate completion date of January 6, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award...
- The Defense Logistics Agency (DLA) issued a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/mL, a biologic pharmaceutical product. Awarded on January 8, 2026, this firm fixed-price delivery order is issued without set-aside designation and reflects DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The place of performance is Park Ridge, Illinois, with an ultimate completion date of January 9, 2026. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for FASENRA Pen 30 MG/ML. The award, issued on January 9, 2026, with an ultimate completion date of January 12, 2026, utilizes firm fixed-price pricing with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense...
- The Defense Logistics Agency issued a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/ml on January 8, 2026, with an ultimate completion date of January 9, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded this firm fixed-price delivery order without a set-aside designation. The award represents one of numerous delivery orders issued under DMS Pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $4,887.00, is for the supply of FASENRA PEN 30 MG/MLML, a pharmaceutical product. This delivery order is under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group that has a ceiling value of up to $499,999,999 and runs through December 31, 2025. The IDC allows DLA to...
- The Defense Logistics Agency awarded a $4,987.50 firm fixed-price delivery order for FASENRA Pen 30 mg/ml to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order, issued on January 9, 2026 with an ultimate completion date of January 12, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,550.00 by the Defense Logistics Agency (DLA) on September 12, 2025. The delivery order, which is scheduled for completion by October 3, 2025, covers the supply of FASENRA Pen 30 mg/mL, a prescription pharmaceutical product, with performance to take place in Conshohocken, Pennsylvania. This award was made without a...
- The Defense Logistics Agency awarded a $9,975 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA PEN 30 MG/ML. This delivery order, issued on January 9, 2026, with an ultimate completion date of January 12, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical...
- The Defense Logistics Agency has awarded a delivery order valued at $9,774.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA 30 mg/ml syringes. DMS Pharmaceutical Group Inc. is a critical supplier within the federal pharmaceutical supply chain and has been registered in the System for Award Management since 2001. This delivery order was issued without a set-aside designation, reflecting the...
- SPE2DR25D9131Indefinite Delivery Contract
- SPE2DR25D9131-SPE2DR26FCPH4Delivery Order
The Defense Logistics Agency issued a delivery order valued at $4,987.50 to DMS Pharmaceutical Group Inc. for FASENRA PEN 30 MG/ML on January 15, 2026, with a completion date of January 16, 2026. This firm fixed-price delivery order was awarded without a set-aside designation to the woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. DMS Pharmaceutical Group, which has maintained a System for Award Management registration since 2001, serves as a critical supplier within the federal pharmaceutical supply chain, with particular focus on supporting Department of Defense medical facilities. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and authorizes DLA to issue delivery orders for a comprehensive portfolio of pharmaceutical products including branded and generic prescription drugs, biologics, vaccines, and medical consumables to support military healthcare operations globally. The contract structure includes a 30-month base period with three 30-month option periods extending through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor supplying diverse pharmaceutical requirements across the federal military medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 1/14/26 |